Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

NovelTAP

Financiado

Cerrado

Novel diagnostic Tools for Alzheimer s and Parkinson s diseases

Neurodegeneration associated with Parkinson’s (PD) and Alzheimer’s (AD) diseases begins several years prior to the appearance of clinical symptoms and in total, over eight million people in Europe were living with PD or AD in year... ver más

30/06/2014

EPFL

160K€

Presupuesto del proyecto: 160K€

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2014-06-30 No tenemos la información de la convocatoria

0% 93% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

1 Participantes

EPFL

0.00€ | Lider

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

PID2020-117656RB-I00 DESARROLLO DE NUEVAS HERRAMIENTAS DIAGNOSTICAS Y ESTRATEGIAS... 316K€ Cerrado

PID2021-126584OA-I00 UNCOVERING COMPOUNDS WITH ABILITY TO BLOCK EARLY AMYLOID SEE... 133K€ Cerrado

Oligomers Characterising protein oligomers and their role in neurodege... 2M€ Cerrado

BIOFINDER New biomarkers for Alzheimer s Parkinson s diseases key... 2M€ Cerrado

PTQ-11-04806 Desarrollo de un test diagnóstico para la enfermedad de Alzh... 83K€ Cerrado

ADDIA Validation of a fast and simple peripheral blood diagnostic... 5M€ Cerrado

Líder del proyecto

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 160K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Neurodegeneration associated with Parkinson’s (PD) and Alzheimer’s (AD) diseases begins several years prior to the appearance of clinical symptoms and in total, over eight million people in Europe were living with PD or AD in year 2010. Currently, there are no diagnostic tools which allow for early diagnose and/or monitoring the progression these diseases in living patients and the available therapeutic methods only offer transient symptomatic relief. Increasing evidence suggest that early diagnosis and intervention are crucial for any future therapeutic strategies to treat and/or slow the progression of these devastating diseases. The target of the PoC project is to establish the innovation potential of using the antibodies developed by the PI as diagnostic tools in PD and AD. To fulfill this target, testing and commercialization activities will take place. Specifically, the PoC project will focus on the in-vitro and in-vivo testing of the antibodies using the blood and the cerebrospinal fluid obtained post-mortem from PD and AD patients as well as from animal transgenic models. If successful, these novel antibodies would enable the development of preclinical diagnostic tools for detecting and measuring protein aggregation and other biomarkers, which could ultimately lead to the development of novel and desperately needed pre-diagnostic and therapeutic strategies for treating and/or preventing neurodegeneration in PD and AD. With the help of the PI’s research team, the Technology Transfer Office of EPFL and subcontractors, the PI will develop a commercialization roadmap required to establish proof of concept.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores